Nolvadex is bad for the eyes too
Effects on the Eye: Ocular disturbances, including corneal changes, decrement in color
vision perception, retinal vein thrombosis, and retinopathy have been reported in patients
receiving NOLVADEX. An increased incidence of cataracts and the need for cataract
surgery have been reported in patients receiving NOLVADEX.
In the NSABP P-1 trial, an increased risk of borderline significance of developing
cataracts among those women without cataracts at baseline (540-NOLVADEX; 483-
placebo; RR=1.13, 95% CI: 1.00-1.28) was observed. Among these same women,
NOLVADEX was associated with an increased risk of having cataract surgery (101-
NOLVADEX; 63-placebo; RR=1.62, 95% CI 1.18-2.22) (See Table 3 in CLINICAL
PHARMACOLOGY). Among all women on the trial (with or without cataracts at
baseline), NOLVADEX was associated with an increased risk of having cataract surgery
(201-NOLVADEX; 129-placebo; RR=1.58, 95% CI 1.26-1.97). Eye examinations were
not required during the study. No other conclusions regarding non-cataract ophthalmic
events can be made.